ResMed's Tariff Exemption Should Support Multiples -- Market Talk

Dow Jones

Apr 28

0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 27, 2025 21:20 ET (01:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2530952894"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530952894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530952894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-28 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530952894","market":"sg","top_or_hot":-1,"title":"ResMed's Tariff Exemption Should Support Multiples -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0120 GMT - ResMed's bull at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2025 21:20 ET (01:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed's Tariff Exemption Should Support Multiples -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed's Tariff Exemption Should Support Multiples -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-28 09:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0120 GMT - ResMed's bull at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2025 21:20 ET (01:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思迈","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530952894","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530952894","pubTimestamp":1745803200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈","BK4504":"桥水持仓","BK7501":"新冠治疗股","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK7007":"医疗保健设备","BK4588":"碎股","BK4082":"医疗保健设备","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","RMD.AU":"Resmed DRC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC"},"translate_title":"瑞思迈的关税豁免应该会支持倍数——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2025 21:20 ET (01:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}